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Summary: Kininase I (carboxypeptidase N; EC 3.4.17.3) consists of carboxypeptidase NI (CNi) and carboxy-
peptidase N2 (CNi); these two enzymes can be differentiated by their activities towards hippuryl-L-arginine
and hippuryl-L-lysine, respectively. A Spectrophotometric assay for both carboxypeptidases in human serum
is described and the biochemical behaviour of these enzymes investigated. The pH optima are found to be 8.4
for CNi and CN2. The Michaelis- Menten constants are: CNi 4.59 ± 0.03 mmol/i; CN2 37.26 ± 3.49 mmol/1.
CN2 can be inhibited by EDTA (76%), dimercaprolum (97%) and phenanthroline (98%). Diisopropylfluo-
rophosphate has no influence on both enzymes. Elevated haemoglobin only interferes with CNi measure-
ments, and high bilirubin concentfations slightly alter the activity of both enzymes. High CNi activities were
found in sera of patients with sarcoidosis, and elevated CN2 activities were found in lung cancer.
Eine einfache spektralphotometrische Methode zur Bestimmung der Carboxypeptidase N (Kininase I) im
menschlichen Serum
Zusammenfassung: Die Carboxypeptidase N (CN; EC 3.4.17.3), auch Kininase I genannt, läßt sich aufgrund
ihres unterschiedlichen biologischen Verhaltens in CNi mit Hippuryl-L-arginin und CN2 mit Hippuryl-L-
lysin als Enzymsubstrat unterscheiden. Beide im Serum enthaltenen Enzyme spalten die terminalen Amino-
säuren ab und lassen dadurch Hippursäure entstehen, deren Konzentration spektralphotometrisch gemessen
wird. CNi und CN? wurden biochemisch charakterisiert. Das pH Optimum lag bei 8,4. Die Michaelis- Menten-
Konstante betrug: CN! 4,59 4 0,03 mfnol/1, CN2 37,29 ± 3,49 fnmol/1. CN2 wurde zu 76% durch EDTA,
Dimercaprol (97%) und Phenanthrolin (98%) inhibiert. Diisopropylfluorophosphat hatte keinen Einfluß auf
beide Enzyme. Erhöhtes Hämoglobin interferierte bei der CNi, Bilirubin zeigte nur eine geringe Interferenz.
Klinische Bedeutung scheint der CNi bei der Lungensarkoidose zuzukommen, bei der die höchsten Aktivitä-
ten im Gegensatz zu anderen Lungenerkrankungen gefunden wurden. Beim Lungenkarzinom war CN2 er-
höht.
Introduction
An enzyme capable of rapidly releasing carboxyl-
terminal lysine and äfginine from peptides has been
found in the bovine pancreas (1). This enzyme was
named carboxypeptidase B (EC 3.4.17.3) or basic
carboxypeptidase and was also purified (2) and char-
acterized (3, 4). Other tissues also have carboxypep-
tidase B activity (5, 6). In human plasma, carboxy-
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J. Clin. Chem. Clin. Biochem. / Vol. 21,1983 / No. 10
peptidase B-like activity was found, which differs
from the isolated pancreas enzyme in molecular
weight, the velöcity of hydrolysis of lysine-contain-
ing Substrates compared to arginine-containing sub-
strätes, and Inhibition patterns (7). Additionally, it
inactivates the nonapeptide bradykinin by removing
the C-terminal arginine; therefore it is also called
kininase I. In human plasma, carboxypeptidase N
has a molecular weight of 280000. Left Standing it
dissociates to subunits of 45000 and 90000 (8). The
plasma enzyme activity was low in some diseases of
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the liver, which indicate that the liver and not the
pancreas is the site of enzyme synthesis. The physio-
logical and pathophysiological role of this aminopep-
tidase in human body fluid has not yet been tho-
roughly clarified. One reason for the lack of interest
in this enzyme may be that the known methods are
not routinely practiced in clinical laboratories.
Therefore we developed a simple spectrophotomet-
ric method for the determination of this carboxypep-
tidase. This assay is based on the estimation of hip-
puric acid formed by carboxypeptidase N from two
synthetic Substrates.
Carboxypeptidase NI (CNi) cleaves the synthetic
Substrate hippuryl-L-arginine, while carboxypepti-
dase N2 (CN2) is used for Splitting the hippuryl-L-ly-
sine. After biochemical characterisation of both en-
zymes, this method was applied to a large number of
untreated sera in various lung diseases.
Materials and Methods
Reagents
Hippuric acid, hippuryl-L-arginine, hippuryl-L-lysine, diisopro-
pylfluorophosphate, ethylenediaminetetra-acetic acid (EDTA),
dimercaprolum, phenanthroline, bilirubin and haemoglobin were
purchased from Sigma, Munich.
AH other chemicals of high purity were obtained from Merck,
Darmstadt. Test tubes were from Sarstedt, Stuttgart. In all assays
distilled and deionized water was used.
0.05 mol/1 hippuryl-L-arginine solution, molecular weight 335.4,
was prepared by dissolving 167.7 mg hippuryl-L-arginine in 10 ml
of 0.5 mol/1 potassium phosphate buffer, pH 8.4; 0.1 mol/1 hip-
puryl-L-lysine solution, molecular weight 307.3, was mixed by
dissolving 307.3 mg hippuryl-L-lysine also in 10 ml of the same
buffer. The buffer was prepared by mixing solution A (containing
87 g/l (0.5 mol/1) K2HPO4 and 43.8 g/l (0.75 mol/1) NaCl) and
solution B (containing 68.0 g/l (0.5 mol/1) KH2PO4 and 43.8 g/l
(0.75 mol/1) NaCl). A sufficieiit quantity of solution B was added
to 100ml of solution A to achieve a pH of 8.4 at 20 °C.
The buffer was stored at 4 °C, which caused some precipitation,
but the precipitate redissolved at 20 °C.
Serum samples
Blood was collected from healthy controls and from patients with
various diseases under the following conditions: Arm venipunc-
ture was performed at 7.30 a. m. after fasting for 2 h and bed rest,
with no administration of drugs during the preceding 24 h. The
healthy donors had lh h bed rest. The blood was allowed to clot in
a 10ml polypropylene test tube. Blood was centrifugated for
10 min at 1200 g in a Heraeus cryofuge at 4 °C, and the supernat-
ant was carefully removed and stored at -20°C until assay.
Incubat ion procedure
50 μΐ serum for measurement of CN,, or 25 μΐ serum for CN2, was
added to 200 μΐ of Substrate buffer solution containing hippuryl-
L-arginine or hippuryl-L-lysine in duplicated 4 ml polypropylene
test tubes, tightly covered, vortexed for 15 s and incubated for
60 min at 37 °C in a temperature controlled shaker water bath.
The enzymatic reaction was stopped by addition of 250 μί of l
mol/1 HC1 solution and vortexed for 15 s. The blanks were sim-
ilary treated except that after addition of serum the enzymatic
reaction was stopped at once by 250 μΐ of l mol/1 HC1 before in-
cubation.
All samples were removed from the water bath and placed in
crushed ice for 5min. Afterwards, 1500μΙ ethyl acetate were
added, vortexed for 30s and centrifuged for 10min at 4000g.
l ml of the upper layer (ethyl acatate) was pipetted into a 4 ml test
tube and placed in a boiling water bath for 45-60 min to evapo-
rate the ethyl acetate thoroughly. 3 ml of l mol/1 NaCl solution
was added to each tube and vortexed for 30 s. All samples were
placed in a water bath at 70 °C for 5 min to redissolve all the re-
sidual hippuric acid, then vortexed for 30 s. After 15 min Standing
at foom temperature, the absorbance of the hippuric acid was
read in a l-cm rectangular cuvette at 228 nm in a Hitachi preci-
siori spectralphotometer 100—40, with distilled deionized w ter
s a blank.
As internal Standard serum, a pool serum of normal persons was
used.
Calculat ion of catalyt ic ac t iv i ty
l Unit (U) of carboxypeptidase N activity is defined s the
amount of enzyme required to release l μηιοί hippuric acid per
min at 37 °C under Standard assay conditions in l ml sefum (i. e.,
U/ml = kU/l = μτηοΐ/ml · min).
A228 * 105 x 3 or A?28X 167.36 for CN ι980 x 079Ϊ x "0767 x"6 x~ Vn ~ A228 x 334.72 fof CN2
_ Absorbance samplei + Absorbance sample2
l— Absorbance blank
980m2 x
0.91
0.67
60
Vn
105
6228 hippuric acid
fraction of extracted hippuric acid
fraction of sarnpled ethyl acetate
incubation time in min
VCNI = 0.050 ml serum fof CNi
VCN2 - 0.025 ml serum for CN2
coriversion to liter
Statistical calculations were performed with Studenfs t-test. For
correlation Spearman rank test was used.
Additionally, ro tine lab ratory parameters were evaluated frorri
the same serum samples used for enzymatic measurements.
Results
Since samples are stored in crushed ice before incu-
bation, there is a time lag before the incubation mix-
ture attains 37 °C. For this reason the course of reac-
tion of the carboxypeptidases did not achieve lineari-
ty until after 10^20 min, using hippuryl-L-argifiine
or hippuryl-L-lysine s synthetic Substrates. The
reaction was still linear up to 120 min (fig. 1). In o f
foutine assay we used an incubation time of 60 min,
which clearly guarantees linearity.
The pKUdependence of CNi and CN2 was investigat-
ed, using potassium phosphate buffer. In repeated
assays CNi showed a small peak of activity at pH 8.4
(fig. 2). For CNi a broad pH Optimum was found be-
tween 8.2 and 8.6. In s bsequent enzymatic reac-
tions, we also used pH 8.4 for
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Fig. 1. Effect of incubation time on carboxypeptidase NI catalytic
activity concentration (© O) and on carboxypepti-
dase N2 catalytic activity concentration (Q D) in se-
ruiri.
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Fig. 2. Effect of pH on carboxypeptidase NI catalytic activity
concentration in serum, measured s the rate of hydrolysis
of hippuryUL-arginine.
Linearity of the assay could also be proven by serum
dilution (fig. 3). CN activity was plotted s dilution
factor. The linear regression analysis gave (CNir ==?
0.99, CN2r = 0.98).
To iiivestigate the dependence of catalytic activity on
the incubation temperat re, incubations were per-
formed between -f 2 °C and +63~5C in a'heated water
bath, CNi showed highest activity at 40 °C, CN2 at
41°C<fig.5).
Fig. 3. Relationship between carboxypeptidase NI (O O)
and carboxypeptidase N: catalytic activity concentrations
(B D) to serum dilution.
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Fig. 4. Stability of carboxypeptidase NI (O ©) and carboxy-
peptidase Na (H —Q) catalytic activity concentration in
serum stored at — 20 °C during 12 months.
The stability of CNi and CN2 was tested during st r-
age at —20 PC for up to 12 months. Only slight de-
creases of CNj (9.3%) and CN2 (5.3%) were ob-
served (fig. 4).
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Fig. 5. Effect of incubation temperature on carboxypeptidase NI
(O O) and carboxypeptidase Na (E D) catalytic
activity concentrations in serum, measured under the as-
say conditions described in text.
Michaelis Menten constants (Km) were determined
by the Linewater Burk plot. The following Km values
were found.
CNi: 4.59 ± 0.03 (SD) mmol/1, (n = 4),
Vmax 19.11 ± 5.68 /1-min;
CN2: 37.29 ± 3.49 mmol/1, (n = 3),
Vmax 147.82 ± 32.21 mol/l·min.
Thus, the affinity of CNi for hippuryl-L-arginine is
greater than the affinity of CN2 for hippuryl-L-ly-
sine.
Blocking agents were also tested (tab. 1). EDTA in-
hibits only CN2 (76%) and shows no Inhibition of
CN2 could be nearly totally blocked by dimercapro-
lum (97%), but CNt was inhibited by only 54%.
Similiar results were obtained for Inhibition by phen-
Tab. L Inhibitor concentrations necessary to produce 50% In-
hibition (Iso) of carboxypeptidase NI (CNi) and N2 (CN2)
measured under Standard assay conditions described in
the text.
Blocking agent
Iso (mmol/l)
CN, . CN2
Diisopropylfluorophosphate none
EDTA none
Phenanthroline 0.59
Dimefcaprolum 9.70
none
3.16
0.15
2.41
anthroline: CNi (64%), CN2 (98%). Diisopropyl-
fluorophosphate had no inhibitöry effect on CNi or
CN2 activity, but the curves suggest a sligbt activa?
tion of both enzymes.
The interference of bilkubin and haemoglobin was
also tested. Initially bilirubin redüced carboxypepti-
dase activity slightly. Only CNi activity was de^
creäsed by additiön of haemoglobin.
For the precision of these methods see table 2.
We measured CNi an4 CN2 in heaLthy controls and
in patients with various Jung diseases (tab. 3). No
positive correlatipn could be found in 47 normal
subjects between cholesterol (CNn r = 0.04; CN2 r
= 0.08) and tfiglycerides (CNi: f = 0.01; CN2 f =
0.10). Significantly elevated activities of CNi were
found in sera of patients with safcöidosis
(p < 0.0001) compared with thehealthy controls aind
with lung cancer patients (p < 0.002). CN2 was sig-
nificäntly increased in patients with lung cancer
(p < 0.0001) compared with cbrftrols and with saiv
coidosis patients (p < 0.02).
Discussion
Our interest in carboxypeptidase was prompted by
our studies of the angiotensin-I^converting enzyme
in lung diseases. Angiotensm-I-converting enzyme
was found to be elevated in sarcoidosis (9) and liver
diseases (10). Similar behaviour by other carboxy-
peptidases in human blood was expected.
The method described here for the determination of
and CN2 activity in serum by spectrpphotomet-
Tab. 2. Precision data of assayed serum to estimate the variability (CV %) of the method.
Carboxypeptidase N i (U/l)
Mean SD CV %
In t ra assay 39.9
Interassay (day to day) 30.3
±0.6 1.8 (n
±2.1 7.1 (n
Cärboxypeptidase N? <U/1)
Mean SD CV%
= 16) 155.8
=°30) 156.3
+ 2.9 1.9 (n = 15)
± 5.1 . . 3.3 (n = 28)
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Tab. 3. Carboxypeptidase NI and Na catalytic concentrations in serum of patients with lung diseases compared with heaithy controls. In
sarcoidosis CNi was significantly elevated (p < 0.002) and CN2 was redüced (p < 0.02) compared with lung cancer.
Carboxypeptidase N i (U/l)
n P<
214
Carboxypeptidase N2 (U/l)
n
241
P<
Sarcoidosis
Lung tuberculosis
Lung cancer
Asthma
Pneumonia
Chronic bronchitis
Heaithy controls
73.9 ± 32.4
37.8 ± 15.7
54.3 ± 25.5
39.5 ± 12.7
43.2 ± 2 1.8
50.1 ± 17.5
36.1 ± 9.9
40
32
54
18
9
14
47
0.0001
0.50
0.0001
0.50
0.20
0.002
177,1 ±41.8
138.5 ±37.3
195.3 ± 38.4
166.9 ±29.7
174.0 ±43.6
167.4 ± 34.4
144.2 ± 26.0
43
33
52
26
13
20
54
0.0001
0.50
0.0001
0.001
0.01
0.01
ric assessment of the cleavage of synthetic Substrates,
is accurate and simple to perform.
Previous reports showed that human serum CN
could be separated by isoelectric focusing into two
subunits (12). The subunits of CN could also be dis-
tinguished by immunological methods (13). It was
speculated that CN consists of two species which
were apparently isoenzymes (12).
With our method, which is derived from the spectro-
photometric measurement of angiotensin-I^convert-
ing enzyme (9), we also foutid differences in bio-
chemical behaviour between CNi and CNz. The pH
curve showed a broad pH Optimum when using hip-
puryl-L-lysine äs Substrate. The ATm-values indicate
that the affinity of the enzyme activity to hippuryl-L-
arginine is greater than to hippuryl-L-lysine. Only
CN2 could be inhibited by EDTA, CNi was not in-
fluenced by this chelating agent.
For comparison, the Km of carboxypeptidase B,
which cleäves the same Substrates, is 0.21 x 10~3
mol/1 for hippuryl-L-arginine and 7.7 x l O"3 mol/1
for hippüryl-L-lysine (11). This shows that CNi re-
moves the C terminal argiiiine faster than lysine.
Pancreatic carböxypeptidase B acts in the same way,
but the Inhibition patterns show differences between
carboxypeptidase B and CN.
Previous studies, using hippuryl-L-lysine äs enzyme
Substrate, describe normal values of carboxypepti-
dase N in pregnant women and in some patients with
tumours. Redüced activity was found in patients with
cirrhosis of the liver (14,15), which indicate that this
enzyme may be synthesized in liver tissue. This could
result in a decreased inactivation of bradykinin and
other vasodilatating peptides in liver diseases. We
measured CNi and CNa in patients with lung dis-
eases and found high activities of CNi in sarcoidosis,
and high activities of CN2 in lung cancer compared
with heaithy controls. Initial investigations indicate
that the elevation of CNi in sarcoidosis is a better
parameter of clinical activity than angiotensin-I-con-
verting enzyme. Like angiotensin-I-converting en-
zyme, the source of CNi may be the epitheloid cells.
There is some evidence that CN2 is produced by ma-
lignant tumour cells.
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